Evidence map›Paper›PMID 17554495›Full record

ArticleJournal of neuro-oncology2007

Pentavalent technetium-99m dimercaptosuccinic acid [99m Tc-(V)DMSA] brain scintitomography--a plausible non-invasive depicter of glioblastoma proliferation and therapy response.

Spyridon Tsiouris, Ioannis Pirmettis, Theodoros Chatzipanagiotou, Nikolaos Ptohis, Vassilios Papantoniou

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Classic tumour imaging agents for glioma evaluation: 99mTc-tetrofosmin.European journal of nuclear medicine and molecular imaging · 2007
    Article
  8. Dimercaptosuccinic acid: A multifunctional cost effective agent for imaging and therapy.Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Spyridon TsiourisNuclear Medicine Department, Alexandra University Hospital, 80, Vas. Sophia's Avenue & 2, K. Lourou Street, Athens 115 28, Greece. spytsi@gmail.com
Ioannis Pirmettis
Theodoros Chatzipanagiotou
Nikolaos Ptohis
Vassilios Papantoniou
Alexandra Hospital · GRMetropolitan Hospital · GRNational Centre of Scientific Research "Demokritos" · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The biological behavior and prognosis of gliomas depend largely on cellular proliferation, resistance to chemotherapy, and metastatic potential. Proliferative propensity has significant implications on patient management but its assessment requires tissue sampling; the non-invasive estimation of brain tumor proliferation represents therefore a major goal. Pentavalent technetium-99 m dimercapto-succinic acid [99m Tc-(V)DMSA] is a tumor-seeking radiotracer displaying affinity for gliomas; its intracellular accumulation is directly linked to cell proliferation. We performed a tomographic 99m Tc-(V)DMSA brain scan in a 35-year-old male baring a recurrent glioblastoma multiforme, to depict its proliferative disposition. The patient had been diagnosed 14 months earlier and had been submitted to surgery, followed by adjuvant radiotherapy and temozolomide-based chemotherapy. On clinical suspicion of recurrence 5 months later, magnetic resonance imaging (MRI) revealed a lesion at the site of preceded surgery, which was treated by imatinib mesylate. No improvement was ascertained the following months and radiographic assessment verified tumor progression. Scintitomography revealed avid radiotracer uptake in the entirety of the lesion (the distribution of radioactivity closely conforming to the morphological tumor boundaries), an indication that the neoplasm demonstrated no substantial proliferation decline in response to imatinib. The patient deceased a few weeks later. Mounting in vivo and in vitro evidence indicates that 99m Tc-(V)DMSA is a credible non-invasive proliferation depicter, its cellular accumulation linked closely to phosphate uptake and kinase pathway activation. A potential role in patient management, prognosis estimation, and therapy response monitoring could occur for this tracer.

Indexed as

RadiopharmaceuticalsTechnetium Tc 99m Dimercaptosuccinic AcidAdultAntineoplastic AgentsBenzamidesBrainBrain NeoplasmsCell ProliferationFatal OutcomeGlioblastomaHumansImatinib MesylateMaleNeoplasm InvasivenessNeoplasm Recurrence, LocalPiperazinesAntineoplastic AgentsBenzamidesImatinib MesylatePiperazinesPyrimidinesRadiopharmaceuticalsTechnetium Tc 99m Dimercaptosuccinic Acid

Identifiers

PMID17554495
OpenAlexW1982045138

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.